FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109716616> ?p ?o ?g. }

• W3109716616 endingPage "282" @default.
• W3109716616 startingPage "266" @default.
• W3109716616 abstract "Adjuvant nutritional treatment is a commonly overlooked topic when treating lethal viral diseases as COVID-19 pandemic. We recently introduced TaibUVID nutritional supplements (nigella sativa, chamomile and natural honey) as adjuvants for COVID-19 contacts, patients and public prophylaxis. TaibUVID Forte adds costus, senna and fennel to TaibUVID. Meta-analyses and systematic reviews confirmed evidence-based therapeutic benefits of TaibUVID components in treating many human diseases e.g. diabetes mellitus and hypertension, common co-morbidities in COVID-19 patients. Double-blind clinical trials for treating COVID-19 patients with TaibUVID supplements were inapplicable. In this retrospective study in Egypt, COVID-19 patients and contacts knew TaibUVID via social media and voluntarily used them. 65% of COVID-19 patients (n = 13) received both pharmacological treatments and adjuvant TaibUVID nutritional supplements. 35% (n = 7) received TaibUVID only. Lymphopenia rapidly improved to lymphocytosis upon regular TaibUVID intake. TaibUVID nutritional supplements helped COVID-19 contacts' prophylaxis. 70% of COVID-19 contacts (n = 14) (on regular TaibUVID intake) did not get SARS-COV2 infection. 30% (n = 6) were not using TaibUVID regularly and got mild flu-like symptoms and upon using both TaibUVID and pharmacological treatments, all improved and got negative nasopharyngeal swabs PCR. COVID-19 contacts were mainly physicians (40%, n = 8) (dealing with COVID-19 patients daily) and members of physicians' families (45%). Main presentations reported by COVID-19 patients (n = 20) were cough (90%), fever (55%), anosmia (45%), taste loss (45%), sore throat (45%), respiratory difficulty (45%) and malaise (35%). TaibUVID inhalation therapy (nigella sativa/anthemis/costus solution nebulization) was used by 65% of COVID-19 patients (n = 13) and alleviated respiratory manifestations e.g. cough and respiratory difficulty and was life-saving in some cases. 70% of COVID-19 patients (n = 14) improved in 1-4 days, 25% (n = 5) improved in 5-10 days while 5% improved in more than 10 days. TaibUVID nutritional supplements were tolerable and significantly satisfactory (P<0.01). 81.25% of COVID-19 patients (n = 13) did not report side effects. 18.25% (n = 3) reported mild diarrhea, sweating and hyperglycemia (not confirmed to be due to TaibUVID supplements). 31.25% of patients (n = 5) were satisfied by 100% with TaibUVID nutritional supplements. 37.5% (n = 6) of patients were satisfied by 75%. In conclusion, TaibUVID nutritional supplements are recommended for public prophylaxis (to decrease emergence of new cases) and treatment in COVID-19 pandemic. Clinical trials and further investigations are recommended." @default.
• W3109716616 created "2020-12-07" @default.
• W3109716616 creator A5003440178 @default.
• W3109716616 creator A5004794175 @default.
• W3109716616 creator A5014507895 @default.
• W3109716616 creator A5027655887 @default.
• W3109716616 creator A5028997382 @default.
• W3109716616 creator A5039450109 @default.
• W3109716616 creator A5042244328 @default.
• W3109716616 creator A5052694356 @default.
• W3109716616 creator A5059471369 @default.
• W3109716616 creator A5060834472 @default.
• W3109716616 creator A5064565224 @default.
• W3109716616 creator A5068336096 @default.
• W3109716616 creator A5073094950 @default.
• W3109716616 creator A5073931573 @default.
• W3109716616 creator A5080099771 @default.
• W3109716616 creator A5081029029 @default.
• W3109716616 creator A5087366365 @default.
• W3109716616 creator A5087486179 @default.
• W3109716616 date "2020-01-01" @default.
• W3109716616 modified "2023-10-16" @default.
• W3109716616 title "Promising preventive and therapeutic effects of TaibUVID nutritional supplements for COVID-19 pandemic: towards better public prophylaxis and treatment (A retrospective study)." @default.
• W3109716616 cites W1593236475 @default.
• W3109716616 cites W1967361627 @default.
• W3109716616 cites W1968875122 @default.
• W3109716616 cites W1972849285 @default.
• W3109716616 cites W1996350719 @default.
• W3109716616 cites W2011173283 @default.
• W3109716616 cites W2011417273 @default.
• W3109716616 cites W2022791060 @default.
• W3109716616 cites W2032311286 @default.
• W3109716616 cites W2033374941 @default.
• W3109716616 cites W2034219423 @default.
• W3109716616 cites W2034590103 @default.
• W3109716616 cites W2041017058 @default.
• W3109716616 cites W2042173556 @default.
• W3109716616 cites W2078195506 @default.
• W3109716616 cites W2080798377 @default.
• W3109716616 cites W2087973684 @default.
• W3109716616 cites W2091059410 @default.
• W3109716616 cites W2097056441 @default.
• W3109716616 cites W2115459196 @default.
• W3109716616 cites W2119497316 @default.
• W3109716616 cites W2136734135 @default.
• W3109716616 cites W2152688067 @default.
• W3109716616 cites W2154853392 @default.
• W3109716616 cites W2413658938 @default.
• W3109716616 cites W2512635391 @default.
• W3109716616 cites W2537883091 @default.
• W3109716616 cites W2579938580 @default.
• W3109716616 cites W2790005483 @default.
• W3109716616 cites W2798092602 @default.
• W3109716616 cites W2891830568 @default.
• W3109716616 cites W2902521063 @default.
• W3109716616 cites W2938830639 @default.
• W3109716616 cites W3013060960 @default.
• W3109716616 cites W3016263963 @default.
• W3109716616 cites W3021652956 @default.
• W3109716616 cites W799791999 @default.
• W3109716616 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7675122" @default.
• W3109716616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33224571" @default.
• W3109716616 hasPublicationYear "2020" @default.
• W3109716616 type Work @default.
• W3109716616 sameAs 3109716616 @default.
• W3109716616 citedByCount "10" @default.
• W3109716616 countsByYear W31097166162020 @default.
• W3109716616 countsByYear W31097166162022 @default.
• W3109716616 countsByYear W31097166162023 @default.
• W3109716616 crossrefType "journal-article" @default.
• W3109716616 hasAuthorship W3109716616A5003440178 @default.
• W3109716616 hasAuthorship W3109716616A5004794175 @default.
• W3109716616 hasAuthorship W3109716616A5014507895 @default.
• W3109716616 hasAuthorship W3109716616A5027655887 @default.
• W3109716616 hasAuthorship W3109716616A5028997382 @default.
• W3109716616 hasAuthorship W3109716616A5039450109 @default.
• W3109716616 hasAuthorship W3109716616A5042244328 @default.
• W3109716616 hasAuthorship W3109716616A5052694356 @default.
• W3109716616 hasAuthorship W3109716616A5059471369 @default.
• W3109716616 hasAuthorship W3109716616A5060834472 @default.
• W3109716616 hasAuthorship W3109716616A5064565224 @default.
• W3109716616 hasAuthorship W3109716616A5068336096 @default.
• W3109716616 hasAuthorship W3109716616A5073094950 @default.
• W3109716616 hasAuthorship W3109716616A5073931573 @default.
• W3109716616 hasAuthorship W3109716616A5080099771 @default.
• W3109716616 hasAuthorship W3109716616A5081029029 @default.
• W3109716616 hasAuthorship W3109716616A5087366365 @default.
• W3109716616 hasAuthorship W3109716616A5087486179 @default.
• W3109716616 hasConcept C126322002 @default.
• W3109716616 hasConcept C141071460 @default.
• W3109716616 hasConcept C197934379 @default.
• W3109716616 hasConcept C2777054765 @default.
• W3109716616 hasConcept C2777870961 @default.
• W3109716616 hasConcept C2777914695 @default.
• W3109716616 hasConcept C2779277585 @default.
• W3109716616 hasConcept C556039675 @default.
• W3109716616 hasConcept C71924100 @default.
• W3109716616 hasConceptScore W3109716616C126322002 @default.

• next